{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:40:15Z","timestamp":1739904015649,"version":"3.37.3"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2002,4]]},"DOI":"10.1124\/dmd.30.4.464","type":"journal-article","created":{"date-parts":[[2003,1,15]],"date-time":"2003-01-15T23:17:35Z","timestamp":1042672655000},"page":"464-478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Oxidative Biotransformation of Losoxantrone (CI-941)"],"prefix":"10.1016","volume":"30","author":[{"given":"Ulf D.","family":"Renner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Piperopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Gebhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Ehninger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus-Peter","family":"Zeller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.30.4.464_bib1","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1039\/p29890002097","article-title":"Electrochemical reduction of the antitumor anthrapyrazole CI-941: mechanism of formation and isolation of the leuco form.","volume":"1989","author":"Anne","year":"1989","journal-title":"J Chem Soc Perkin Trans II"},{"key":"10.1124\/dmd.30.4.464_bib2","first-page":"301","article-title":"Correlation of proton and nitrogen-15 chemical shifts by multiple quantum NMR.","volume":"55","author":"Bax","year":"1983","journal-title":"J Magn Reson"},{"key":"10.1124\/dmd.30.4.464_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/jhet.5570260117","article-title":"Anticancer anthrapyrazoles. Improved synthesis of clinical agents CI-937, CI-941, and piroxantrone hydrochloride.","volume":"26","author":"Beylin","year":"1989","journal-title":"J Heterocyclic Chem"},{"key":"10.1124\/dmd.30.4.464_bib4","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0090-9556(25)08188-7","article-title":"Detection and identification of human urinary metabolites of biantrazole (CI-941).","volume":"21","author":"Blanz","year":"1993","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.30.4.464_bib5","first-page":"71","article-title":"Phase II study of losoxantrone in previously treated and untreated patients with advanced breast cancer (CA).","volume":"13","author":"Calvert","year":"1994","journal-title":"Proc Am Soc Oncol"},{"key":"10.1124\/dmd.30.4.464_bib6","first-page":"299","article-title":"A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.","volume":"5","author":"Diab","year":"1999","journal-title":"Clinical Cancer Research"},{"key":"10.1124\/dmd.30.4.464_bib7","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1432-1033.1993.tb17854.x","article-title":"Identification and functional characterization of regulatory elements of the glutamine synthetase gene from rat liver.","volume":"213","author":"Fahrner","year":"1993","journal-title":"Eur J Biochem"},{"key":"10.1124\/dmd.30.4.464_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0163-7258(91)90089-5","article-title":"Biochemical pharmacology of anthracenediones and anthrapyrazoles.","volume":"52","author":"Fry","year":"1991","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.30.4.464_bib9","first-page":"213","article-title":"Inactivation of lactate dehydrogenase during freezing in the presence of metyrapone: implications for in vitro cytotoxicity studies.","volume":"13","author":"Gebhardt","year":"2000","journal-title":"In Vitro Mol Toxicol"},{"key":"10.1124\/dmd.30.4.464_bib10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/BF00120803","article-title":"Influence of hormones and drugs on glutathione S-transferase levels in primary culture of adult rat hepatocytes.","volume":"6","author":"Gebhardt","year":"1990","journal-title":"Cell Biol Toxicol"},{"key":"10.1124\/dmd.30.4.464_bib11","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1016\/0006-2952(87)90309-1","article-title":"The effect of the anthrapyrazole antitumor agent CI941 on rat liver microsome and cytochrome P-450 reductase mediated free radical processes.","volume":"36","author":"Graham","year":"1987","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.30.4.464_bib12","first-page":"1333","article-title":"A multicenter phase II trail of losoxantrone (Dup-941) in hormone-refractory metastatic prostate cancer.","volume":"6","author":"Huan","year":"2000","journal-title":"Clin Can Res"},{"key":"10.1124\/dmd.30.4.464_bib13","first-page":"96","article-title":"Elimination pathways of [14C]losoxantrone in four cancer patients.","volume":"29","author":"Joshi","year":"2001","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 8","key":"10.1124\/dmd.30.4.464_bib14","first-page":"39","article-title":"Paclitaxel and anthracycline combination chemotherapy for metastatic breast cancer.","volume":"26","author":"Kaufman","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1124\/dmd.30.4.464_bib15","first-page":"124a","article-title":"Losoxantrone and paclitaxel versus paclitaxel alone as first line chemotherapy for metastatic breast cancer (MBC): final results of a phase III randomized trail.","volume":"17","author":"Kaufman","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1124\/dmd.30.4.464_bib16","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/jnci\/86.16.1239","article-title":"Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen.","volume":"86","author":"Leteurtre","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1124\/dmd.30.4.464_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF00229240","article-title":"The mechanism of action of quinone antibiotics.","volume":"55","author":"Lown","year":"1983","journal-title":"Mol Cell Biochem"},{"key":"10.1124\/dmd.30.4.464_bib18","unstructured":"Mewes K (1993) Biotransformation und Wirkungsmechanismus des Zytostatikums Mitoxantrone, Doctoral dissertation University of T\u00fcbingen, Germany."},{"key":"10.1124\/dmd.30.4.464_bib19","first-page":"5135","article-title":"Cytochrome P-450-induced cytotoxicity of mitoxantrone by formation of electrophilic intermediates.","volume":"53","author":"Mewes","year":"1993","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.30.4.464_bib20","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1021\/jm00195a002","article-title":"1,4-Bis-[(aminoalkyl)amino]-9,10-anthracenediones.","volume":"22","author":"Murdock","year":"1979","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.30.4.464_bib21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0090-9556(25)06511-0","article-title":"Biotransformation of CI-937 in primary cultures of rat hepatocytes. Formation of glutathione conjugates.","volume":"23","author":"Renner","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.30.4.464_bib22","unstructured":"Reszka K, Kolodziejczyk P, Hartley JA, Wilson WD, Lown JA (1988) Molecular pharmacology of anthracenedione-based anticancer agents Anthracycline and anthracenedione-based anticancer agents (Lown JW ed) pp 401\u2013445, Elsevier Science Publishers B.V., Amsterdam."},{"key":"10.1124\/dmd.30.4.464_bib23","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0090-9556(25)06627-9","article-title":"Identification of two regioisomeric monocarboxylic acid metabolites of losoxantrone (DuP 941; biantrazole) excreted in human urine.","volume":"23","author":"Richards","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.30.4.464_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0091-679X(08)61797-5","article-title":"Preparation of isolated rat liver cells.","volume":"13","author":"Seglen","year":"1976","journal-title":"Methods Cell Biol"},{"key":"10.1124\/dmd.30.4.464_bib25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1021\/jm00384a021","article-title":"Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias.","volume":"30","author":"Showalter","year":"1987","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.30.4.464_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0305-7372(83)90008-7","article-title":"Mitoxantrone (novantrone): a review of experimental and early clinical studies.","volume":"10","author":"Smith","year":"1983","journal-title":"Cancer Treat Rev"},{"key":"10.1124\/dmd.30.4.464_bib27","series-title":"New Avenues in Developmental Cancer Chemotherapy","first-page":"355","article-title":"5-Aminoanthrapyrazoles (CI-937; CI-941; CI-942): a novel class of DNA binders with broad-spectrum anticancer activity","author":"Werbel","year":"1987"},{"key":"10.1124\/dmd.30.4.464_bib28","first-page":"229","article-title":"Anthraquinone anticancer agents.","volume":"8","author":"Zee-Cheng","year":"1983","journal-title":"Drugs Future"},{"key":"10.1124\/dmd.30.4.464_bib29","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1016\/S0040-4039(00)73069-3","article-title":"Reversal of regioselectivity of anthrapyrazole Formation. A new synthesis of Losoxantrone (DUP941).","volume":"35","author":"Zhang","year":"1994","journal-title":"Tetrahedron Lett"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624044222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624044222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.30.4.464","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:15:21Z","timestamp":1739902521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624044222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["S0090955624044222"],"URL":"https:\/\/doi.org\/10.1124\/dmd.30.4.464","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2002,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Oxidative Biotransformation of Losoxantrone (CI-941)","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.30.4.464","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2002 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}